
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5779179/publications.pdf Version: 2024-02-01



Ρεπρο Ρ. ΡΔωνολ

#	Article	IF	CITATIONS
1	Antibiotic treatment in patients with sepsis: a narrative review. Hospital Practice (1995), 2022, 50, 203-213.	1.0	6
2	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health. Journal of Mental Health, 2022, 31, 524-533.	1.9	2
3	Choosing antibiotic therapy for severe community-acquired pneumonia. Current Opinion in Infectious Diseases, 2022, 35, 133-139.	3.1	16
4	Pancreatic Stone Protein: Review of a New Biomarker in Sepsis. Journal of Clinical Medicine, 2022, 11, 1085.	2.4	14
5	Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma. Annals of Medicine, 2022, 54, 713-722.	3.8	8
6	Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive and Critical Care Nursing, 2022, 70, 103227.	2.9	80
7	Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study. Intensive Care Medicine, 2022, 48, 690-705.	8.2	38
8	Antibiotic prophylaxis in ICU patients: should I do or not?. Intensive Care Medicine, 2022, 48, 1215-1217.	8.2	1
9	Biomarkers in the ICU: less is more? Not sure. Intensive Care Medicine, 2021, 47, 101-103.	8.2	2
10	Antimicrobial Stewardship in the Intensive Care Unit: The Role of Biomarkers, Pharmacokinetics, and Pharmacodynamics. Advances in Therapy, 2021, 38, 164-179.	2.9	9
11	Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review. Clinical Microbiology and Infection, 2021, 27, 47-54.	6.0	88
12	Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Medicine, 2021, 47, 188-198.	8.2	237
13	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. Critical Care Medicine, 2021, 49, 503-516.	0.9	41
14	Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. Critical Care, 2021, 25, 177.	5.8	69
15	Optimizing Antimicrobial Drug Dosing in Critically Ill Patients. Microorganisms, 2021, 9, 1401.	3.6	27
16	Gut Microbiota Diversity and C-Reactive Protein Are Predictors of Disease Severity in COVID-19 Patients. Frontiers in Microbiology, 2021, 12, 705020.	3.5	57
17	Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 546-556.	5.6	65
18	Which Biomarkers Can Be Used as Diagnostic Tools for Infection in Suspected Sepsis?. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 662-671.	2.1	7

#	Article	IF	CITATIONS
19	When should we use corticosteroids in severe community-acquired pneumonia?. Current Opinion in Infectious Diseases, 2021, 34, 169-174.	3.1	7
20	Ventilator-associated pneumonia diagnosis: a prioritization exercise based on multi-criteria decision analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 281-286.	2.9	12
21	Antifungal use in the surgical ICU patient. Current Opinion in Anaesthesiology, 2020, 33, 131-138.	2.0	2
22	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1612-1621.	0.9	12
23	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1622-1635.	0.9	47
24	International variation in the management of severe COVID-19 patients. Critical Care, 2020, 24, 486.	5.8	55
25	Identification of distinct clinical phenotypes in mechanically ventilated patients with acute brain dysfunction using cluster analysis. Medicine (United States), 2020, 99, e20041.	1.0	4
26	Contributing factors to the plasma albumin level at diagnosis of hematological malignancy. Hospital Practice (1995), 2020, 48, 223-229.	1.0	1
27	Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey. Journal of Critical Care, 2020, 59, 70-75.	2.2	234
28	Longitudinal trajectory patterns of plasma albumin and C-reactive protein levels around diagnosis, relapse, bacteraemia, and death of acute myeloid leukaemia patients. BMC Cancer, 2020, 20, 249.	2.6	11
29	Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Medicine, 2020, 46, 298-314.	8.2	135
30	The role of steroids in severe CAP. Hospital Practice (1995), 2020, 48, 12-22.	1.0	1
31	Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections. Microorganisms, 2020, 8, 165.	3.6	11
32	New biomarkers for respiratory infections. Current Opinion in Pulmonary Medicine, 2020, 26, 232-240.	2.6	7
33	C-reactive protein and albumin kinetics after antibiotic therapy in community-acquired bloodstream infection. International Journal of Infectious Diseases, 2020, 95, 50-58.	3.3	10
34	Any Role for Biomarker-Guide Algorithms in Antibiotic Stewardship Programs?*. Critical Care Medicine, 2020, 48, 775-777.	0.9	5
35	Accuracy of the clinical pulmonary infection score to differentiate ventilator-associated tracheobronchitis from ventilator-associated pneumonia. Annals of Intensive Care, 2020, 10, 101.	4.6	15
36	Symptoms of burnout in intensive care unit specialists facing the COVID-19 outbreak. Annals of Intensive Care, 2020, 10, 110.	4.6	239

#	Article	IF	CITATIONS
37	Subglottic secretion drainage: is reducing VAP enough?. Minerva Anestesiologica, 2020, 86, 805-807.	1.0	1
38	The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. Intensive Care Medicine, 2019, 45, 1753-1762.	8.2	15
39	Leptospirosis: one of the forgotten diseases. Intensive Care Medicine, 2019, 45, 1816-1818.	8.2	2
40	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Medicine, 2019, 45, 1518-1539.	8.2	47
41	Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia. ERJ Open Research, 2019, 5, 00212-2018.	2.6	7
42	Biomarkers in Pulmonary Infections. Clinical Pulmonary Medicine, 2019, 26, 118-125.	0.3	8
43	Outpatient management of community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 2019, 25, 249-256.	2.6	6
44	Response. Chest, 2019, 155, 244-245.	0.8	0
45	Clinical Significance of Viral Detection in Critically III Patients. More Questions Than Answers. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 411-413.	5.6	4
46	Ventilator-associated tracheobronchitis: an update. Revista Brasileira De Terapia Intensiva, 2019, 31, 541-547.	0.3	8
47	Outpatient management of community-acquired pneumonia. Current Opinion in Infectious Diseases, 2018, 31, 170-176.	3.1	6
48	A Comparison of the Quick-SOFA and Systemic Inflammatory Response Syndrome Criteria for the Diagnosis of Sepsis and Prediction of Mortality. Chest, 2018, 153, 646-655.	0.8	182
49	The potential role of exhaled breath analysis in the diagnostic process of pneumonia—a systematic review. Journal of Breath Research, 2018, 12, 024001.	3.0	56
50	Hemodynamic Support. Hot Topics in Acute Care Surgery and Trauma, 2018, , 343-357.	0.1	0
51	Patterns of C-reactive protein ratio response to antibiotics in pediatric sepsis: A prospective cohort study. Journal of Critical Care, 2018, 44, 217-222.	2.2	17
52	Appraisal of systemic inflammation and diagnostic markers in a porcine model of VAP: secondary analysis from a study on novel preventive strategies. Intensive Care Medicine Experimental, 2018, 6, 42.	1.9	4
53	Real-life data patterns of C-reactive protein and albumin level trajectories around bacteremia. Biomarkers in Medicine, 2018, 12, 1251-1259.	1.4	5
54	Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis. Expert Review of Anti-Infective Therapy, 2018, 16, 839-847.	4.4	18

#	Article	IF	CITATIONS
55	C-reactive protein and procalcitonin profile in ventilator-associated lower respiratory infections. Journal of Critical Care, 2018, 48, 385-389.	2.2	19
56	Do we need new trials of procalcitonin-guided antibiotic therapy?. Critical Care, 2018, 22, 17.	5.8	8
57	The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. Thorax, 2017, 72, 803-810.	5.6	118
58	Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. Journal of Critical Care, 2017, 41, 91-97.	2.2	23
59	Tools for outcome prediction in patients with community acquired pneumonia. Expert Review of Clinical Pharmacology, 2017, 10, 201-211.	3.1	24
60	Corticosteroids in Severe Sepsis and Septic Shock. Shock, 2017, 47, 47-51.	2.1	16
61	Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Intensive Care Medicine, 2017, 43, 612-624.	8.2	140
62	Ventilator-associated pneumonia prevention: one good turn does not always deserve another. Intensive Care Medicine, 2017, 43, 1872-1874.	8.2	0
63	Patterns of C-reactive protein ratio predicts outcomes in healthcare-associated pneumonia in critically ill patients with cancer. Journal of Critical Care, 2017, 42, 231-237.	2.2	5
64	The current status of biomarkers for the diagnosis of nosocomial pneumonias. Current Opinion in Critical Care, 2017, 23, 391-397.	3.2	41
65	Long-term physical morbidity in ARDS survivors. Intensive Care Medicine, 2017, 43, 101-103.	8.2	1
66	Biomarker-guided antibiotic therapy—strengths and limitations. Annals of Translational Medicine, 2017, 5, 208-208.	1.7	50
67	Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies. Annals of Translational Medicine, 2017, 5, 450-450.	1.7	26
68	Dear Sepsis-3, we are sorry to say that we don't like you. Revista Brasileira De Terapia Intensiva, 2017, 29, 4-8.	0.3	35
69	Fatal acute necrohaemorrhagic pancreatitis with massive intraperitoneal and retroperitoneal bleeding: a rare cause of exsanguination. BMJ Case Reports, 2016, 2016, bcr2015213732.	0.5	5
70	Duration of antibiotic therapy in the intensive care unit. Journal of Thoracic Disease, 2016, 8, 3774-3780.	1.4	56
71	Prevention and Control of Antimicrobial Resistant Healthcare-Associated Infections: The Microbiology Laboratory Rocks!. Frontiers in Microbiology, 2016, 7, 855.	3.5	21
72	Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Annals of Intensive Care, 2016, 6, 32.	4.6	50

#	Article	IF	CITATIONS
73	ls there a continuum between ventilator-associated tracheobronchitis and ventilator-associated pneumonia?. Intensive Care Medicine, 2016, 42, 1190-1192.	8.2	15
74	Corticosteroids for severe influenza pneumonia: A critical appraisal. World Journal of Critical Care Medicine, 2016, 5, 89.	1.8	33
75	Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. Critical Care, 2015, 19, 193.	5.8	18
76	Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis. Intensive Care Medicine Experimental, 2015, 3, 26.	1.9	15
77	Biomarker Kinetics in VAP. Clinical Pulmonary Medicine, 2015, 22, 185-191.	0.3	2
78	Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respiratory Medicine,the, 2015, 3, 859-868.	10.7	152
79	Corticosteroid therapy for pneumonia. Lancet, The, 2015, 386, 954-955.	13.7	1
80	PIRO and sepsis stratification: reality or mirage?. Revista Brasileira De Terapia Intensiva, 2015, 27, 196-8.	0.3	5
81	Using procalcitonin to guide antimicrobial duration in sepsis: asking the same questions will not bring different answers. Critical Care, 2014, 18, 142.	5.8	16
82	Diagnostic accuracy of C-reactive protein and procalcitonin in the early detection of infection after elective colorectal surgery – a pilot study. BMC Infectious Diseases, 2014, 14, 444.	2.9	46
83	The volatile metabolic fingerprint of ventilator-associated pneumonia. Intensive Care Medicine, 2014, 40, 761-762.	8.2	30
84	Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacology & Toxicology, 2014, 15, 21.	2.4	41
85	Management of severe community-acquired pneumonia: A survey on the attitudes of 468 physicians in Iberia and South America. Journal of Critical Care, 2014, 29, 743-747.	2.2	5
86	Trials of Biomarker-Guided Antimicrobial Therapy in Sepsis. Critical Care Medicine, 2014, 42, e172.	0.9	1
87	Biomarkers to guide the use of corticosteroids in community-acquired pneumonia: A wish rather than a tangible concept. Journal of Infection, 2013, 66, 290.	3.3	2
88	Amphotericin B in Severe Fungal Infections: A Critical Reappraisal of the Evidence. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1032-1032.	5.6	2
89	Severe Diltiazem Poisoning Treated with Hyperinsulinaemia-Euglycaemia and Lipid Emulsion. Case Reports in Critical Care, 2013, 2013, 1-4.	0.4	9
90	Community-acquired pneumonia: identification and evaluation of nonresponders. Therapeutic Advances in Infectious Disease, 2013, 1, 5-17.	1.8	23

#	Article	IF	CITATIONS
91	The Predisposition, Infection, Response and Organ Failure (Piro) Sepsis Classification System: Results of Hospital Mortality Using a Novel Concept and Methodological Approach. PLoS ONE, 2013, 8, e53885.	2.5	37
92	Uso de biomarcadores na sepse: muitas perguntas, poucas respostas. Revista Brasileira De Terapia Intensiva, 2013, 25, 1-2.	0.3	8
93	What is the role of steroids in pneumonia therapy?. Current Opinion in Infectious Diseases, 2012, 25, 199-204.	3.1	20
94	Assessment of risk factors for in-hospital mortality after intensive care unit discharge. Biomarkers, 2012, 17, 180-185.	1.9	15
95	Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Critical Care, 2012, 16, R53.	5.8	64
96	Failure to reduce C-reactive protein levels more than 25% in the last 24 hours before intensive care unit discharge predicts higher in-hospital mortality: A cohort study. Journal of Critical Care, 2012, 27, 525.e9-525.e15.	2.2	33
97	Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Annals of Intensive Care, 2012, 2, 32.	4.6	64
98	Continuous Infusion of Piperacillin/Tazobactam in Septic Critically III Patients—A Multicenter Propensity Matched Analysis. PLoS ONE, 2012, 7, e49845.	2.5	20
99	Prevalência e desfechos das infecções nas UTIs brasileiras: mais uma peça no quebra-cabeça Revista Brasileira De Terapia Intensiva, 2012, 24, 115-116.	0.3	0
100	Treatment of candidemia in adult patients without neutropenia - an inconvenient truth. Critical Care, 2011, 15, 114.	5.8	10
101	C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Critical Care, 2011, 15, R129.	5.8	38
102	Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Critical Care, 2011, 15, R206.	5.8	316
103	Corticosteroids in severe community-acquired pneumonia: the path we choose depends on where we want to get. Critical Care, 2011, 15, 137.	5.8	9
104	C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Critical Care, 2011, 15, R169.	5.8	97
105	Echinocandins - first line in invasive candidiasis: how strong is this 'strong' evidence?. Critical Care, 2011, 15, 461.	5.8	2
106	Novos marcadores biológicos na pneumonia comunitária grave. Revista Brasileira De Terapia Intensiva, 2011, 23, 499-506.	0.3	8
107	Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: A cohort study. Journal of Critical Care, 2011, 26, 193-200.	2.2	46
108	Hydrocortisone and Treatment of Multiple Trauma. JAMA - Journal of the American Medical Association, 2011, 306, 41; author reply 42.	7.4	1

#	Article	IF	CITATIONS
109	Novel biomarkers in severe community-acquired pneumonia. Revista Brasileira De Terapia Intensiva, 2011, 23, 499-506.	0.3	4
110	Biomarkers as end points in clinical trials of severe sepsis: A garden of forking paths*. Critical Care Medicine, 2010, 38, 1749-1751.	0.9	9
111	Corticosteroids for H1N1 associated acute lung injury: is it just wishful thinking?. Intensive Care Medicine, 2010, 36, 1098-1099.	8.2	8
112	Should C-reactive protein concentration at ICU discharge be used as a prognostic marker?. BMC Anesthesiology, 2010, 10, 17.	1.8	26
113	Corticosteroids in Sepsis: Pathophysiological Rationale and the Selection of Patients. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 266-273.	1.2	4
114	Adrenergic Support in Septic Shock: A Critical Review. Hospital Practice (1995), 2010, 38, 62-73.	1.0	14
115	Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study)*. Critical Care Medicine, 2009, 37, 410-416.	0.9	75
116	The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Critical Care, 2008, 12, R76.	5.8	65
117	The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Critical Care, 2008, 12, 434.	5.8	2
118	Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2008, 21, 157-162.	3.1	55
119	Current perspectives for the use of corticosteroids in sepsis: patient selection is the key. Therapy: Open Access in Clinical Medicine, 2008, 5, 797-800.	0.2	0
120	Metformin-induced lactic acidosis: a case series. Journal of Medical Case Reports, 2007, 1, 126.	0.8	33
121	Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Critical Care, 2007, 11, R92.	5.8	83
122	Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Critical Care, 2006, 10, R63.	5.8	118
123	C-reactive protein as a marker of infection in critically ill patients. Clinical Microbiology and Infection, 2005, 11, 101-108.	6.0	247
124	Pilot Study Evaluating C-Reactive Protein Levels in the Assessment of Response to Treatment of Severe Bloodstream Infection. Clinical Infectious Diseases, 2005, 40, 1855-1857.	5.8	54
125	C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. European Respiratory Journal, 2005, 25, 804-812.	6.7	143
126	Evaluation of a recruitment maneuver with positive inspiratory pressure and high PEEP in patients with severe ARDS. Acta Anaesthesiologica Scandinavica, 2004, 48, 287-293.	1.6	37

#	Article	IF	CITATIONS
127	C-reactive protein: a valuable marker of sepsis. Intensive Care Medicine, 2002, 28, 235-243.	8.2	331
128	Plasma catecholamines and postural hypotension in familial amyloidotic polyneuropathy of the Portuguese type. Clinical Autonomic Research, 1991, 1, 271-274.	2.5	6
129	Autonomic function in patients with familial amyloidotic polyneuropathy and their relatives. Journal of the Autonomic Nervous System, 1990, 31, 172.	1.9	1
130	Updated competency-based training in intensive care: next step towards a healthcare union in Europe?. Intensive Care Medicine, 0, , .	8.2	4